Halozyme Therapeutics (HALO) Change in Inventory (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Change in Inventory data on file, last reported at -$27.4 million in Q1 2026.

• On a quarterly basis, Change in Inventory fell 4772.18% year-over-year to -$27.4 million in Q1 2026; TTM through Mar 2026 was -$30.5 million, a 210.04% decrease from a year earlier, with the FY2025 full-year figure at -$2.6 million, down 103.79% from the prior year.
• Change in Inventory for Q1 2026 stood at -$27.4 million, down from -$18.8 million in the prior quarter.
• Over the last five years, Change in Inventory for HALO reached as high as $40.2 million in Q1 2024 and fell as low as -$27.4 million in Q1 2026.
• Historically, Change in Inventory has averaged $4.8 million across 5 years, with a median of $2.9 million in 2022.
• Across the five-year window, Change in Inventory soared 17717.44% in 2022 and plunged 4772.18% in 2026, its largest moves.
• Year by year, Change in Inventory stood at $2.9 million in 2022, then plunged by 149.88% to -$1.5 million in 2023, then surged by 625.94% to $7.7 million in 2024, then sank by 343.09% to -$18.8 million in 2025, then slumped by 45.78% to -$27.4 million in 2026.
• Per Business Quant data, the three most recent Change in Inventory figures were -$27.4 million in Q1 2026, -$18.8 million in Q4 2025, and $1.1 million in Q3 2025.